British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer

Sudha Sundar, Andy Nordin, Jo Morrison, Nick Wood, Sadaf Ghaem-Maghami, Jo Nieto, Andrew Phillips, John Butler, Kevin Burton, Rob Gornall, Stephen Dobbs, Rosalind Glasspool, Richard Peevor, Jonathan Ledermann, Iain McNeish, Nithya Ratnavelu, Timothy Duncan, Jonathan Frost, Kenneth Lim, Agnieszka MichaelElly Brockbank, Ketankumar Gajjar, Alexandra Taylor, Rebecca Bowen, Adrian Andreou, Raji Ganesan, Shibani Nicum, Richard Edmondson, Richard Clayton, Janos Balega, Phil Rolland, Hilary Maxwell, Christina Fotopoulou

Research output: Contribution to journalArticlepeer-review


Ovarian cancer survival in the UK lags behind comparable countries. Results from the ongoing National Ovarian Cancer Audit feasibility pilot (OCAFP) show that approximately 1 in 4 women with advanced ovarian cancer (Stage 2, 3, 4 and unstaged cancer) do not receive any anticancer treatment and only 51% in England receive international standard of care treatment, i.e., the combination of surgery and chemotherapy. The audit has also demonstrated wide variation in the percentage of women receiving anticancer treatment for advanced ovarian cancer, be it surgery or chemotherapy across the 19 geographical regions for organisation of cancer delivery (Cancer Alliances). Receipt of treatment also correlates with survival: 5 year Cancer survival varies from 28.6% to 49.6% across England. Here, we take a systems wide approach encompassing both diagnostic pathways and cancer treatment, derived from the whole cohort of women with ovarian cancer to set out recommendations and quality performance indicators (QPI). A multidisciplinary panel established by the British Gynaecological Cancer Society carefully identified QPI against criteria: metrics selected were those easily evaluable nationally using routinely available data and where there was a clear evidence base to support interventions. These QPI will be valuable to other taxpayer funded systems with national data collection mechanisms and are to our knowledge the only population level data derived standards in ovarian cancer. We also identify interventions for Best practice and Research recommendations.

Original languageEnglish
Article number337
Issue number2
Publication statusPublished - 4 Jan 2023


  • British Gynaecological cancer society
  • ovarian cancer
  • population data
  • quality performance indicators

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer'. Together they form a unique fingerprint.

Cite this